Samsung Bioepis Kicks Off Phase III Pembrolizumab Trial

Follows Recent Initiation Of Phase I Study For SB27 Proposed Keytruda Biosimilar

 
• By David Wallace
  
Clinical Trial Experiment of a New Product
Samsung Bioepis has begun a Phase III trial for its SB27 Pembrolizumab Candidate
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products